

Supplementary Materials: The *Ala54Thr* Polymorphism of the Fatty Acid Binding Protein 2 Gene Modulates HDL Cholesterol in Mexican-Americans with Type 2 Diabetes

Lorena M. Salto, Liming Bu, W. Lawrence Beeson, Anthony Firek, Zaida Cordero-MacIntyre and Marino De Leon

Table S1. Baseline to three-month *En Balance* participant changes for the combined group ($n = 43$).

	Baseline	Three-Month	Mean Difference	<i>p</i> -Value ^a
	Mean \pm SD	Mean \pm SD	\pm SD	
Fasting Blood Glucose (mg/dl)	162.5 \pm 73.4	143.1 \pm 58.8	19.5 \pm 46.1	0.008 *
HbA1c (%)	8.1 \pm 2.5	7.3 \pm 1.8	0.79 \pm 1.51	0.001 *
Insulin (uU/mL)	14.1 \pm 9.9	15.2 \pm 12.7	1.13 \pm 7.35	0.319
HOMA-IR ^b	4.85 \pm 2.86	4.29 \pm 2.49	0.57 \pm 2.26	0.119
Total Cholesterol (mg/dl)	187.5 \pm 40.8	176.3 \pm 49.8	11.1 \pm 34.6	0.041 *
HDL Cholesterol (mg/dl)	46.1 \pm 10.4	46.1 \pm 10.2	0.07 \pm 6.86	0.947
LDL Cholesterol (mg/dl)	115.9 \pm 33.4	106.9 \pm 36.2	8.9 \pm 27.8	0.042 *
Cholesterol: HDL ratio	4.2 \pm 1.1	3.9 \pm 1.1	0.27 \pm 0.75	0.022 *
Triglycerides (mg/dl)	207.6 \pm 121.7	189.8 \pm 118.2	17.8 \pm 82.9	0.167
BIA: Fat Mass (kg)	33.7 \pm 13.3	31.9 \pm 13.1	1.7 \pm 3.1	0.001 *
BIA: Fat %	39.8 \pm 9.3	38.3 \pm 9.2	1.45 \pm 2.35	<0.001 *
BIA: Fat-free Mass (kg)	48.2 \pm 9.4	48.8 \pm 9.4	0.57 \pm 1.67	0.038 *
Weight (kg)	81.3 \pm 18.3	80.9 \pm 17.9	0.41 \pm 2.59	0.317
Waist Circumference (cm)	100.4 \pm 13.4	98.7 \pm 13.2	1.66 \pm 5.24	0.055
Hip Circumference (cm)	110.8 \pm 15.6	110.6 \pm 14.6	0.20 \pm 3.36	0.695
Waist to Hip Ratio	0.91 \pm 0.07	0.89 \pm 0.06	0.01 \pm 0.05	0.067
BMI (kg/m ²)	32.5 \pm 7.1	32.0 \pm 6.9	0.42 \pm 1.04	0.012 *
DXA: Trunk Fat (kg)	16.2 \pm 6.5	15.8 \pm 6.3	0.40 \pm 1.05	0.015 *
DXA: Trunk Lean (kg)	25.5 \pm 4.8	25.4 \pm 4.9	0.02 \pm 1.04	0.885
DXA: Trunk Percent Fat (%)	37.4 \pm 8.9	36.9 \pm 8.7	0.52 \pm 1.72	0.043 *
DXA: Total Fat (kg)	31.0 \pm 12.4	30.4 \pm 12.0	0.64 \pm 1.61	0.013 *
DXA: Total Lean (kg)	49.2 \pm 9.9	49.2 \pm 10.2	0.05 \pm 1.60	0.838
DXA: Total Percent Fat (%)	36.9 \pm 9.0	36.4 \pm 9.0	0.45 \pm 1.19	0.018*

BIA = bioelectrical impedance analysis; BMI= body mass index; DXA = dual-energy X-ray absorptiometry;

^a This *p*-value is based on paired-samples *t*-test or Wilcoxon signed-ranks test comparing baseline to three-month changes; * *p*-value < 0.05; ^b Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) = [fasting insulin (mU/L) \times fasting glucose (mmol/L)] / 22.5.

Table S2. Results of linear regression analyses of baseline marker levels adjusted for the *Ala54Thr* polymorphism ^a on primary endpoint changes (Δ^b), ($n = 43$).

Linear Regression Model ($\hat{Y} = \alpha + \beta X_1 + \beta X_2 + \epsilon_i$)	Baseline Marker	Baseline Marker <i>p</i> -value ^c	<i>Ala54Thr</i> <i>p</i> -Value
$\Delta\text{FBG} = \alpha + \beta\text{FBG_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	Fasting Blood Glucose (mg/dl)	<0.001 *	0.958
$\Delta\text{HbA1c} = \alpha + \beta\text{HbA1c_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	HbA1c (%)	<0.001 *	0.231
$\Delta\text{Insulin} = \alpha + \beta\text{Insulin_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	Insulin (uU/mL)	0.607	0.550
$\Delta\text{HOMA-IR} = \alpha + \beta\text{HOMA-IR_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	HOMA-IR	<0.001 *	0.513
$\Delta\text{Cholest.} = \alpha + \beta\text{Cholest_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	Total Cholesterol (mg/dl)	0.406	0.856
$\Delta\text{HDL} = \alpha + \beta\text{HDL_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	HDL Cholesterol (mg/dl)	0.070	0.421
$\Delta\text{LDL} = \alpha + \beta\text{LDL_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	LDL Cholesterol (mg/dl)	0.047 *	0.939
$\Delta\text{Chol:HDL} = \alpha + \beta\text{Chol:HDL_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	Cholesterol: HDL ratio	0.064	0.509
$\Delta\text{Trig.} = \alpha + \beta\text{Trig_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	Triglycerides (mg/dl)	0.013 *	0.888
$\Delta\text{BIAFM} = \alpha + \beta\text{BIAFM_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	BIA: Fat Mass (kg)	0.297	0.589
$\Delta\text{BIAFat\%} = \alpha + \beta\text{BIAFat\%_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	BIA: Fat %	0.359	0.786
$\Delta\text{BIAFFM} = \alpha + \beta\text{BIAFFM_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	BIA: Fat Free Mass (kg)	0.635	0.899
$\Delta\text{Wt} = \alpha + \beta\text{Wt_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	Weight (kg)	0.147	0.946
$\Delta\text{WC} = \alpha + \beta\text{WC_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	Waist Circumference (cm)	0.138	0.829
$\Delta\text{HC} = \alpha + \beta\text{HC_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	Hip Circumference (cm)	0.007 *	0.416
$\Delta\text{W2H} = \alpha + \beta\text{W2H_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	Waist to Hip Ratio	<0.001 *	0.610
$\Delta\text{BMI} = \alpha + \beta\text{BMI_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	BMI (kg/m ²)	0.120	0.943
$\Delta\text{DXATrunkFat} = \alpha + \beta\text{DXATrunkFat_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	DXA: Trunk Fat (kg)	0.065	0.899
$\Delta\text{DXATrunkLean} = \alpha + \beta\text{DXATrunkLean_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	DXA: Trunk Lean (kg)	0.787	0.670
$\Delta\text{DXATrunk\%Fat} = \alpha + \beta\text{DXATrunk\%Fat_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	DXA: Trunk Percent Fat (%)	0.145	0.354
$\Delta\text{DXATotalFat} = \alpha + \beta\text{DXATotalFat_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	DXA: Total Fat (kg)	0.077	0.953
$\Delta\text{DXATotalLean} = \alpha + \beta\text{DXATotalLean_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	DXA: Total Lean (kg)	0.290	0.716
$\Delta\text{DXATotal\%Fat} = \alpha + \beta\text{DXATotal\%Fat_bl} + \beta\text{Ala54Thr_group} + \epsilon_i$	DXA: Total Percent Fat (%)	0.622	0.581

^a Ala/Ala (*Ala54* homozygotes, G/G genotype) vs. Ala/Thr and Thr/Thr (*Thr54* allele carriers, G/A and A/A genotypes combined); ^b Δ : Three-month -Baseline Change; ^c This *p*-value is based on the effect of the baseline marker as a predictor of the dependent change variable using the linear regression model shown; * *p*-value < 0.05.